Fcγ receptor type IIIA polymorphisms influence treatment outcomes in patients with inflammatory arthritis treated with tumor necrosis factor α–blocking agents
Version of Record online: 2 SEP 2005
Copyright © 2005 by the American College of Rheumatology
Arthritis & Rheumatism
Volume 52, Issue 9, pages 2693–2696, September 2005
How to Cite
Tutuncu, Z., Kavanaugh, A., Zvaifler, N., Corr, M., Deutsch, R. and Boyle, D. (2005), Fcγ receptor type IIIA polymorphisms influence treatment outcomes in patients with inflammatory arthritis treated with tumor necrosis factor α–blocking agents. Arthritis & Rheumatism, 52: 2693–2696. doi: 10.1002/art.21266
- Issue online: 2 SEP 2005
- Version of Record online: 2 SEP 2005
- Manuscript Accepted: 3 JUN 2005
- Manuscript Received: 9 MAR 2005
- NIH General Clinical Research Center. Grant Number: M01-RR-00827
- 4A triallelic Fcγ receptor type IIIA polymorphism influences the binding of human IgG by NK cell FcγRIIIa. J Immunol 1996; 156: 3948–55., , , , , , et al.
- 12Evidences that anti tumor necrosis factor therapy with both etanercept and infliximab induces apoptosis in macrophages but not lymphocytes in RA joints [abstract]. Arthritis Rheum 2004; 50 Suppl 9: S373., , , , .